Combined E7-dendritic cell-based immunotherapy and human sodium/iodide symporter radioiodine gene therapy with monitoring of antitumor effects by bioluminescent imaging in a mouse model of uterine cervical cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 6, 2011, Pages 671-679

  Jeon, Yong Hyun ^a   Lee, Ho Won ^a   Lee, You La ^a   Kim, Jung Eun ^a   Hwang, Mi Hye ^a   Jeong, Shin Young ^a   Lee, Sang Woo ^a   Ahn, Byeong Cheol ^a   Ha, Jeoung Hee ^b   Lee, Jaetae ^a  

^a Kyungpook National University Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

combination therapy; dendritic cells (DCs); human sodium iodide symporter gene (hNIS); radioiodine gene therapy; vaccination

Indexed keywords

CELL ANTIGEN; IODINE 131; RADIOACTIVE IODINE; SODIUM IODIDE SYMPORTER; TECHNETIUM 99M;

ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; UTERINE CERVIX CANCER; VACCINATION; XENOGRAFT;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GREEN FLUORESCENT PROTEINS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOTHERAPY, ADOPTIVE; IODINE RADIOISOTOPES; LUMINESCENT MEASUREMENTS; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; SYMPORTERS; TRANSFECTION; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83455262915     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.1081     Document Type: Article

References (44)

1. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997;9:10.
2. Hart DN. Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood 1997;90:3245.
3. Steinman RM. The dendritic cell system and its role in im-munogenicity. Annu Rev Immunol 1991;9:271.
4. Ardavin C, Amigorena S, Reis e Sousa C. Dendritic cells: Immunobiology and cancer immunotherapy. Immunity 2004;20:17.
5. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour pep-tides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297.
6. Ossevoort MA, Feltkamp MC, van Veen KJ, et al. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papilloma-virus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 1995;18:86.
7. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997;15:94.
8. Carbone FR, Moore MW, Sheil JM, et al. Induction of cyto-toxic T lymphocytes by primary in vitro stimulation with peptides. J Exp Med 1988;167:1767.
9. Tuting T, DeLeo AB, Lotze MT, et al. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol 1997;27:2702.
10. Arthur JF, Butterfield LH, Roth MD, et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997;4:17.
11. Dietz AB, Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998; 91:392.
12. Nair SK, Snyder D, Rouse BT, et al. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997;70:706.
13. Ashley DM, Faiola B, Nair S, et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997;186:1177.
14. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117:1195.
15. Chung JK. Sodium iodide symporter: Its role in nuclear medicine. J Nucl Med 2002;43:1188.
16. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458.
17. Spitzweg C, Dietz AB, O'Connor MK, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 2001;8:1524.
18. Kang JH, Chung JK, Lee YJ, et al. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy. J Nucl Med 2004;45:1571.
19. Lee YJ, Chung JK, Shin JH, et al. In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid 2004;14:889.
20. Spitzweg C, O'Connor MK, Bergert ER, et al. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000;60:6526.
21. Chen L, Altmann A, Mier W, et al. Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene. J Nucl Med 2006;47:854.
22. Jeon YH, Choi Y, Yoon SO, et al. Synergistic tumoricidal effect of combined hMUC1 vaccination and hNIS radio-iodine gene therapy. Mol Cancer Ther 2008;7:2252.
23. Jeon YH, Choi Y, Kim CW, et al. Human sodium/iodide symporter-mediated radioiodine gene therapy enhances the killing activities of CTLs in a mouse tumor model. Mol Cancer Ther 2010;9:126.
24. Wang TL, Ling M, Shih IM, et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 2000; 7:726.
25. Cheng WF, Hung CF, Chai CY, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001;108:669.
26. Hsieh CJ, Kim TW, Hung CF, et al. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 2004;22:3993.
27. Shen Z, Reznikoff G, Dranoff G, et al. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997;158:2723.
28. Kim JH, Kang TH, Noh KH, et al. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8 (+) T cell-mediated cell death. Immunol Lett 2009;122:58.
29. Kim D, Hung CF, Wu TC. Monitoring the trafficking of adoptively transferred antigen-specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther 2007;18:575.
30. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21.
31. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004;104:2235.
32. Nicolette CA, Healey D, Tcherepanova I, et al. Dendritic cells for active immunotherapy: Optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine 2007;25 Suppl 2:B47.
33. Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol 2000;74:181.
34. Whiteside TL. Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects. Adv Exp Med Biol 1998;451:167.
35. Vallabhajosula S. Radiopharmaceuticals in oncology. In: Khalkhali I, Maublant IC, Goldsmith SJ, eds. Nuclear Oncology: Diagnosis and Therapy. Philadelphia, PA: Lippincot, Williams & Wilkins, 2001:31.
36. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338.
37. Chakraborty M, Wansley EK, Carrasquillo JA, et al. The use of chelated radionuclide (samarium-153-ethylenediaminete-tramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res 2008;14:4241.
38. Demaria S, Bhardwaj N, McBride WH, et al. Combining radiotherapy and immunotherapy: A revived partnership. Int J Radiat Oncol Biol Phys 2005;63:655.
39. Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985.
40. Wilson T, Hastings JW. Bioluminescence. Annu Rev Cell Dev Biol 1998;14:197.
41. De A, Lewis XZ, Gambhir SS. Noninvasive imaging of lentiviral-mediated reporter gene expression in living mice. Mol Ther 2003;7:681.
42. Jeon YH, Choi Y, Kim HJ, et al. In vivo bioluminescence visualization of antitumor effects by human MUC1 vaccination. Mol Imaging 2007;6:297.
43. Contag CH, Jenkins D, Contag PR, et al. Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia 2000;2:41.
44. Jenkins DE, Hornig YS, Oei Y, et al. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple meta-stases in immune deficient mice. Breast Cancer Res 2005; 7:R444.